Ekkehard Beck

2.5k total citations · 1 hit paper
77 papers, 1.2k citations indexed

About

Ekkehard Beck is a scholar working on Infectious Diseases, Health and Physiology. According to data from OpenAlex, Ekkehard Beck has authored 77 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Infectious Diseases, 20 papers in Health and 20 papers in Physiology. Recurrent topics in Ekkehard Beck's work include Vaccine Coverage and Hesitancy (20 papers), Asthma and respiratory diseases (18 papers) and SARS-CoV-2 and COVID-19 Research (17 papers). Ekkehard Beck is often cited by papers focused on Vaccine Coverage and Hesitancy (20 papers), Asthma and respiratory diseases (18 papers) and SARS-CoV-2 and COVID-19 Research (17 papers). Ekkehard Beck collaborates with scholars based in United States, Belgium and Germany. Ekkehard Beck's co-authors include Eric D. Bateman, Wolfgang Seibold, Petra Moroni-Zentgraf, Huib A.M. Kerstjens, Mark Vandewalker, Ralf Sigmund, Michael Engel, Pierluigi Paggiaro, Ronald Dahl and Kinga Meszaros and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Diabetes.

In The Last Decade

Ekkehard Beck

66 papers receiving 1.2k citations

Hit Papers

Tiotropium in Asthma Poorly Controlled with Standard Comb... 2012 2026 2016 2021 2012 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy
    2012 476 citations Ekkehard Beck et al. profile →

Peers

Ekkehard Beck
Patricia Correll Australia
Liping Huang United States
Ryan D. Madanick United States
Ami Buikema United States
Robert T. Chen United States
Arthur L. Frank United States
J Prignot Belgium
Baranov Aa Russia
Mingshan Xue China
André Schultz Australia
Patricia Correll Australia
Ekkehard Beck
Citations per year, relative to Ekkehard Beck Ekkehard Beck (= 1×) peers Patricia Correll

Countries citing papers authored by Ekkehard Beck

Since Specialization
Citations

This map shows the geographic impact of Ekkehard Beck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ekkehard Beck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ekkehard Beck more than expected).

Fields of papers citing papers by Ekkehard Beck

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ekkehard Beck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ekkehard Beck. The network helps show where Ekkehard Beck may publish in the future.

Co-authorship network of co-authors of Ekkehard Beck

This figure shows the co-authorship network connecting the top 25 collaborators of Ekkehard Beck. A scholar is included among the top collaborators of Ekkehard Beck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ekkehard Beck. Ekkehard Beck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kohli, Michele, et al.. (2026). Modeling the cost-effectiveness of the next-generation COVID-19 mRNA-1283 vaccine in the United States. Journal of Medical Economics. 29(1). 574–593.
2.
Joshi, Keya, et al.. (2025). Clinical Impact and Cost-Effectiveness of Updated 2023/24 COVID-19 mRNA Vaccination in High-Risk Populations in the United States. Infectious Diseases and Therapy. 14(6). 1219–1238. 2 indexed citations
3.
Buck, Philip O., Ekkehard Beck, Noam Y. Kirson, et al.. (2024). New Vaccine Platforms—Novel Dimensions of Economic and Societal Value and Their Measurement. Vaccines. 12(3). 234–234. 2 indexed citations
4.
Sevilla, J.P., Daniel L. Tortorice, David Kantor, et al.. (2024). Lifecycle model-based evaluation of infant 4CMenB vaccination in the UK. The European Journal of Health Economics. 25(7). 1133–1146.
5.
6.
Beck, Ekkehard, Elisha Beebe, Daina B. Esposito, et al.. (2024). Evaluating the Effectiveness of mRNA-1273.815 Against COVID-19 Hospitalization Among Adults Aged ≥ 18 Years in the United States. Infectious Diseases and Therapy. 14(1). 199–216. 5 indexed citations
7.
Kohli, Michele, Michael Maschio, Keya Joshi, et al.. (2024). The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2024 vaccines in the United Kingdom. Journal of Medical Economics. 27(1). 1359–1372. 2 indexed citations
8.
9.
Aris, Emmanuel, et al.. (2024). Burden of vaccine-preventable diseases in adults (50+) in the United States: a retrospective claims analysis. BMC Public Health. 24(1). 2960–2960. 3 indexed citations
10.
Nguyễn, Văn Hùng, Alina Bogdanov, Cathérine Boileau, et al.. (2024). Comparative effectiveness of the bivalent COVID-19 mRNA vaccines, mRNA1273-222 and BNT162b2, in immunocompromised adults in the US.. Journal of Clinical Oncology. 42(16_suppl). e23057–e23057. 1 indexed citations
11.
12.
Joshi, Keya, Stefan Scholz, Michael Maschio, et al.. (2023). Clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2023 vaccines in Germany. Journal of Medical Economics. 27(1). 39–50. 9 indexed citations
13.
Kohli, Michele, Michael Maschio, Keya Joshi, et al.. (2023). The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States. Journal of Medical Economics. 26(1). 1532–1545. 16 indexed citations
14.
Looker, Katharine J, et al.. (2023). The potential public health impact of adolescent 4CMenB vaccination on Neisseria gonorrhoeae infection in England: a modelling study. BMC Public Health. 23(1). 1–1. 52 indexed citations
15.
Beck, Ekkehard, Nancy Devlin, Mark Doherty, et al.. (2022). Capturing the value of vaccination within health technology assessment and health economics: Literature review and novel conceptual framework. Vaccine. 40(30). 4008–4016. 20 indexed citations
16.
Scholz, Stefan, Magdalena Schwarz, Ekkehard Beck, et al.. (2021). Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease. Infectious Diseases and Therapy. 11(1). 367–387. 11 indexed citations
17.
Beck, Ekkehard, Véronique Abitbol, Örjan Åkerborg, et al.. (2020). Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: An application to England. Vaccine. 38(47). 7558–7568. 19 indexed citations
18.
Chapman, Kenneth R., et al.. (2016). Overall and Cardiovascular Safety of Aclidinium Bromide in Patients With COPD: A Pooled Analysis of Six Phase III, Placebo-Controlled, Randomized Studies. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 3(1). 435–445. 6 indexed citations
19.
Beck, Ekkehard, Michelle Birkett, Benjamin Armbruster, & Brian Mustanski. (2015). A Data-Driven Simulation of HIV Spread Among Young Men Who Have Sex With Men. JAIDS Journal of Acquired Immune Deficiency Syndromes. 70(2). 186–194. 45 indexed citations
20.
Beck, Ekkehard, Hari Balasubramanian, & Philip L. Henneman. (2009). Resource management and process change in a simplified model of the emergency department. Winter Simulation Conference. 1887–1895. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Patricia Correll Breakdown of academic impact, for papers by Liping Huang Breakdown of academic impact, for papers by Ryan D. Madanick Breakdown of academic impact, for papers by Ami Buikema Breakdown of academic impact, for papers by Robert T. Chen Breakdown of academic impact, for papers by Arthur L. Frank Breakdown of academic impact, for papers by J Prignot Breakdown of academic impact, for papers by Baranov Aa Breakdown of academic impact, for papers by Mingshan Xue Breakdown of academic impact, for papers by André Schultz
Rankless by CCL
2026